| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 | Dec'07 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash flows provided by (used in) operating activities: | ||||||||||||
Net (loss) earnings | ||||||||||||
1,131,500 | -379,300 | 1,813,400 | 304,600 | 146,200 | 719,200 | 778,600 | 752,900 | 760,000 | 596,900 | 717,400 | 848,600 | 773,200 |
Adjustments to reconcile net (loss) earnings to cash provided by operating activities: | ||||||||||||
Depreciation and amortization | ||||||||||||
1,006,100 | 1,040,500 | 1,062,700 | 1,039,300 | 712,400 | 375,800 | 358,500 | 363,100 | 359,900 | 340,200 | 337,400 | 275,100 | 230,000 |
Gain on sale of investments | ||||||||||||
- | - | - | - | - | - | - | - | - | - | - | 38,800 | 0 |
In-process research and development | ||||||||||||
- | - | - | - | - | - | - | - | - | - | - | 38,500 | 6,500 |
Net curtailment and settlement | ||||||||||||
- | - | - | - | - | - | - | - | - | - | 32,100 | - | 0 |
Share-based compensation | ||||||||||||
84,300 | 65,500 | 53,700 | 57,300 | 46,400 | 49,400 | 48,500 | 55,000 | 60,500 | 62,000 | 75,300 | 69,900 | 70,100 |
Biomet merger consideration compensation expense | ||||||||||||
- | - | - | - | 90,400 | - | 0 | - | - | - | - | - | - |
Goodwill impairment | ||||||||||||
- | - | - | - | - | - | - | 96,000 | - | 204,000 | 73,000 | - | 0 |
Goodwill and intangible asset impairment | ||||||||||||
70,100 | 979,700 | 331,500 | 31,100 | - | - | - | - | - | - | - | - | - |
Income tax benefit from stock option exercises | ||||||||||||
- | - | - | - | - | - | 38,400 | -11,000 | -12,900 | 4,200 | 3,500 | 12,500 | 40,800 |
Excess income tax benefit from stock option exercises | ||||||||||||
- | - | - | - | 11,800 | 11,100 | 8,600 | 2,700 | 5,000 | 1,300 | 400 | 6,500 | -27,000 |
Inventory step-up | ||||||||||||
- | - | 32,800 | 323,300 | 317,800 | 5,400 | 8,000 | 4,800 | 11,400 | 1,400 | 12,500 | 7,000 | 500 |
Gain on divestiture of assets | ||||||||||||
- | - | - | - | 19,000 | - | - | - | - | - | - | - | - |
Debt extinguishment | ||||||||||||
- | - | - | -53,300 | -22,000 | - | - | - | - | - | - | - | - |
Deferred income tax benefit (provision) | ||||||||||||
-538,700 | 13,400 | -1,776,000 | -153,200 | -164,000 | -90,500 | -126,200 | -64,800 | -19,700 | -72,500 | -19,700 | 2,000 | 63,900 |
Changes in operating assets and liabilities, net of acquired assets and liabilities | ||||||||||||
Income taxes | ||||||||||||
111,400 | -150,800 | 150,200 | -10,900 | 244,700 | -13,200 | 104,400 | 59,200 | 14,600 | 7,700 | 7,000 | -77,300 | 6,100 |
Receivables | ||||||||||||
93,800 | -213,600 | -161,700 | 141,600 | 56,100 | 40,400 | 74,300 | 45,500 | 63,200 | 33,000 | 4,600 | 44,400 | -12,500 |
Inventories | ||||||||||||
125,200 | 199,500 | 120,100 | -77,900 | 205,400 | 164,600 | 148,100 | 67,500 | -7,200 | -25,800 | -36,200 | 148,100 | -58,000 |
Accounts payable and accrued liabilities | ||||||||||||
-42,000 | 155,900 | -133,300 | 32,600 | -252,000 | 116,100 | 33,600 | 47,800 | 20,000 | -800 | -132,600 | 119,300 | 61,900 |
Other assets and liabilities | ||||||||||||
17,900 | -8,400 | -5,700 | -18,500 | 21,800 | -114,400 | 49,700 | 57,400 | -18,300 | -58,900 | -44,600 | 19,700 | -71,100 |
Net cash provided by operating activities | ||||||||||||
1,585,800 | 1,747,400 | 1,582,300 | 1,632,200 | 849,800 | 1,060,500 | 963,100 | 1,151,900 | 1,176,900 | 1,193,500 | 1,117,500 | 1,038,100 | 1,084,400 |
Cash flows provided by (used in) investing activities: | ||||||||||||
Additions to instruments | ||||||||||||
315,900 | 276,300 | 337,000 | 345,500 | 266,400 | 197,400 | 192,900 | 148,900 | 155,400 | 192,500 | 123,700 | -237,900 | -138,500 |
Additions to other property, plant and equipment | ||||||||||||
207,100 | 162,700 | 156,000 | 184,700 | 167,700 | 144,900 | 100,000 | 114,700 | 113,800 | 79,200 | 105,100 | 250,000 | 192,700 |
Purchases of investments | ||||||||||||
- | - | - | 1,500 | 214,800 | 1,350,900 | 732,700 | 1,130,100 | 662,100 | 413,300 | 66,400 | - | - |
Sales of investments | ||||||||||||
- | - | - | 286,200 | 802,900 | 1,282,200 | 830,800 | 878,500 | 394,800 | 67,500 | - | 54,900 | - |
Net investment hedge settlements | ||||||||||||
48,100 | 69,200 | - | - | - | - | - | - | - | - | - | - | - |
Purchases of short-term investments | ||||||||||||
- | - | - | - | - | - | - | - | - | - | - | - | 0 |
Acquisition of intellectual property rights | ||||||||||||
- | - | - | - | - | - | - | - | - | 8,500 | 35,800 | 109,400 | 0 |
Proceeds from divestiture of assets | ||||||||||||
- | - | - | - | 69,900 | - | - | - | - | - | - | - | - |
Business combination investments, net of acquired cash | ||||||||||||
37,100 | 15,300 | 4,000 | 421,900 | - | 54,300 | 74,200 | 59,000 | 56,800 | 82,600 | 39,500 | 18,800 | - |
Proceeds from sale of investments | ||||||||||||
- | - | - | - | - | - | - | - | - | - | - | - | 0 |
Abbott Spine acquisition, net of acquired cash | ||||||||||||
- | - | - | - | - | - | - | - | - | - | - | 363,000 | 0 |
Investments in other assets | ||||||||||||
19,700 | 31,500 | 13,800 | 3,000 | 21,700 | 4,100 | 13,500 | 17,900 | 31,100 | 18,300 | 10,700 | - | 160,300 |
Net cash used in investing activities | ||||||||||||
-729,300 | -416,600 | -510,800 | -1,691,500 | -7,557,900 | -469,400 | -282,500 | -592,100 | -624,400 | -726,900 | -381,200 | -924,200 | -491,500 |
Cash flows provided by (used in) financing activities: | ||||||||||||
Proceeds from senior notes | ||||||||||||
549,200 | 749,500 | - | 1,073,500 | 7,628,200 | -250,000 | - | - | - | - | - | - | - |
Proceeds from multicurrency revolving facility | ||||||||||||
- | 400,000 | 400,000 | - | - | - | - | - | - | - | - | - | - |
Payments on multicurrency revolving facility | ||||||||||||
- | 400,000 | 400,000 | - | - | - | - | - | - | - | - | - | - |
Redemption of senior notes | ||||||||||||
500,000 | 1,150,000 | 500,000 | 1,250,000 | 2,762,000 | - | - | - | - | - | - | - | - |
Proceeds from term loans | ||||||||||||
200,000 | 675,000 | 192,700 | 750,000 | 3,000,000 | - | - | 147,300 | 549,300 | - | 998,800 | - | 0 |
Payments on term loans | ||||||||||||
960,000 | 1,425,000 | 940,000 | 800,000 | 500,000 | - | - | - | - | - | - | - | - |
Net proceeds (payments) under revolving credit facilities | ||||||||||||
- | - | - | - | - | 2,300 | -97,500 | -50,100 | 500 | -2,200 | -330,000 | 330,000 | 0 |
Net payments on other debt | ||||||||||||
-5,300 | -3,900 | -900 | -33,100 | 100 | - | - | - | - | - | - | - | - |
Dividends paid to stockholders | ||||||||||||
196,700 | 195,200 | 193,600 | 188,400 | 157,100 | 145,500 | 132,400 | 94,400 | - | - | - | - | - |
Proceeds from employee stock compensation plans | ||||||||||||
158,200 | 107,900 | 145,500 | 136,600 | 105,200 | 284,700 | 474,800 | 46,900 | 43,400 | 16,900 | 9,500 | 57,000 | 149,800 |
Net cash flows from unremitted collections from factoring programs | ||||||||||||
12,200 | 36,700 | -103,500 | - | - | - | - | - | - | - | - | - | - |
Business combination contingent consideration payments | ||||||||||||
2,900 | 19,800 | 9,100 | - | - | - | - | - | - | - | - | - | - |
Restricted stock withholdings | ||||||||||||
- | - | - | - | 11,100 | 7,700 | - | - | - | - | - | - | - |
Excess income tax benefit from stock option exercises | ||||||||||||
- | - | - | - | 11,800 | 11,100 | 8,600 | 2,700 | 5,000 | 1,300 | 400 | 6,500 | 27,000 |
Debt issuance costs | ||||||||||||
- | - | - | - | 58,400 | 64,100 | - | 3,300 | 4,000 | - | 8,500 | - | 0 |
Other financing activities | ||||||||||||
-10,200 | -4,000 | -8,600 | -16,300 | - | - | - | - | - | - | - | - | - |
Acquisition of noncontrolling interest | ||||||||||||
- | - | - | - | - | - | - | - | - | - | 8,600 | - | 0 |
Repurchase of common stock | ||||||||||||
- | - | - | 415,500 | 150,000 | 400,900 | 720,800 | 485,600 | 1,050,000 | 505,600 | 923,700 | 737,000 | 576,300 |
Net cash provided by financing activities | ||||||||||||
-779,900 | -1,302,200 | -1,210,500 | -743,200 | 7,106,700 | -570,100 | -467,300 | -436,500 | -455,800 | -489,600 | -262,100 | -343,500 | -399,500 |
Effect of exchange rates on cash and cash equivalents | ||||||||||||
-1,500 | -10,200 | 29,300 | -22,700 | -22,600 | -18,300 | -17,000 | -7,300 | 2,700 | 200 | 4,900 | -21,700 | 4,800 |
Increase in cash and cash equivalents | ||||||||||||
75,100 | 18,400 | -109,700 | -825,200 | 376,000 | 2,700 | 196,300 | 116,000 | 99,400 | -22,800 | 479,100 | -251,300 | 198,200 |
Intellectual Property Rights | ||||||||||||
Acquisition of intellectual property rights | ||||||||||||
197,600 | - | - | - | - | - | - | - | - | - | - | - | - |
LDR Holding Corporation [Member] | ||||||||||||
Business acquisition, net of acquired cash | ||||||||||||
- | - | - | 1,021,100 | - | - | - | - | - | - | - | - | - |